ScoreWhy is Kura Oncology, Inc. ?
1
Negative results in Mar 26
- NET SALES(HY) At USD 35.6 MM has Grown at -47.64%
- ROCE(HY) Lowest at -124.74%
- PRE-TAX PROFIT(Q) Fallen at -28.18%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 77.09%, its profits have fallen by -60.2%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Kura Oncology, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Kura Oncology, Inc.
77.09%
-0.82
61.20%
S&P 500
25.22%
1.91
13.23%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
132.87%
EBIT Growth (5y)
-205.45%
EBIT to Interest (avg)
-124.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.77
Sales to Capital Employed (avg)
0.27
Tax Ratio
1.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.93
EV to EBIT
-0.09
EV to EBITDA
-0.09
EV to Capital Employed
-0.06
EV to Sales
0.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-160.03%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET PROFIT(HY)
Higher at USD -154.33 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -515.88 %
RAW MATERIAL COST(Y)
Fallen by 1.72% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 3.48 times
NET SALES(Q)
At USD 18.27 MM has Grown at 29.47%
-18What is not working for the Company
NET SALES(HY)
At USD 35.6 MM has Grown at -47.64%
ROCE(HY)
Lowest at -124.74%
PRE-TAX PROFIT(Q)
Fallen at -28.18%
NET PROFIT(Q)
Fallen at -27.69%
Here's what is working for Kura Oncology, Inc.
Debt-Equity Ratio
Lowest at -515.88 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales
At USD 18.27 MM has Grown at 29.47%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 3.48 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by 1.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Kura Oncology, Inc.
Pre-Tax Profit
Fallen at -28.18%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Fallen at -27.69%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
